No products in the cart.
Tag: Ibrutinib
#VisualAbstract: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to ...
Survival increased in chronic lymphocytic leukemia patients treated with ibrutinib and rituximab
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to ...
Ibrutinib effective for previously treated Waldenström’s macroglobulinemia
1. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, produced a response in 90.5% of patients with Waldenström’s macroglobulinemia. 2. Patient ...
Ibrutinib improves survival in refractory chronic lymphoid leukemia
1. Ibrutinib was superior to ofatumumab in a head-to-head trial in patients who have failed initial therapy for chronic lymphoid ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.